Search
for
Sort by
Research 30 of 1000+
- LB1099 Placebo response in alopecia studies
- Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
- Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury—a randomized, double-blind, and placebo-controlled pilot study
- Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: A randomized, double-blind, and placebo control trial
- Dose-response study of topical minoxidil in male pattern alopecia
- 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
- 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
- Lack of response of alopecia areata to pimecrolimus cream
- Response to: “Minimum requirements for reporting clinical trials evaluating the therapeutic potential of platelet-rich plasma”
- Prognostic factors that affect the response to topical treatment in patchy alopecia areata
- Delaying treatment in male-pattern hair loss affects the therapeutic response
- Effect of the frequency of injection on the clinical responses of postmenopausal women to testosterone enanthate with estradiol valerate
- Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia
- The placebo effect and randomized trials: analysis of conventional medicine
- Supplementary Material for: Turpentine ointment for the treatment of folliculitis – an open, prospective, randomized, placebo- and comparator-controlled multicenter trial
- Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
- 43755 Rapid Reduction and Strict Complete Response in Itch With Oral Difelikefalin in Subjects With Notalgia Paresthetica and Moderate-to-Severe Pruritus
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Supplementary Material for: Turpentine ointment for the treatment of folliculitis – an open, prospective, randomized, placebo- and comparator-controlled multicenter trial
- Turpentine Ointment for the Treatment of Folliculitis: An Open, Prospective, Randomized, Placebo- and Comparator-Controlled Multicenter Trial
- Tratamento da alopecia areata com corticóide tópico: estudo prospectivo randomizado duplo cego em crianças
- Platelet-Rich Plasma in the Management of Alopecia: A Systematic Review and Meta-Analysis of Clinical Evidence
- Efficacy of neutral electrolyzed water vs. common topical antiseptics in the healing of full‑thickness burn: Preclinical trial in a mouse model
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- Efficacy and Safety of Platelet-Rich Plasma Therapy in Alopecia Areata Patients: A Systematic Review
- 281 Phase I/IIa clinical trial for the treatment of androgenetic alopecia using intradermal injections of cultured autologous dermal sheath cup cells
- Placebo effect of topical and oral treatments for androgenetic alopecia A systematic review and meta-analysis
- Placebo effect of topical and oral treatments for androgenetic alopecia A systematic review and meta-analysis
- Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial